Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer

JNCI Journal of the National Cancer Institute 2026 Open access

Read full text
Authors: Yashasvini Sampathkumar, Ziad Zakaria, Kelli O’Connell, Jenna Bhimani, Victoria S. Blinder, Rachael P. Burganowski, Isaac Joshua Ergas, Grace B Gallagher, Jennifer J. Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy
+14 more Candyce H. Kroenke, Cecile A Laurent, Raymond Liu, Maria J. Monroy‐Iglesias, Kanichi G. Nakata, Sonia Persaud, Janise M. Roh, Sara M. Tabatabai, Emily Valice, Peng Wang, Elisa Victoria Bandera, Erin J. Aiello Bowles, L. Kushi, Elizabeth D. Kantor
DOI: 10.1093/jnci/djag063
Cited by: 1
References: 44

Abstract

BACKGROUND: Chemotherapy dose reductions are associated with poorer survival. To better understand the role of clinician- and facility-level factors in chemotherapy dosing, we conducted an analysis within a large, real-world cohort of women with stages I-IIIA breast cancer. METHODS: Our cohort included 8540 breast cancer patients receiving chemotherapy at Kaiser Permanente Northern California between 2006 and 2019. Patients were treated across 22 facilities by 198 clinicians. We evaluated associations between clinician- and facility-level factors related to dose reductions at the start of chemotherapy (first cycle dose proportion, FCDP,

Fields of Study & Subjects

Breast Cancer Treatment Studies Global Cancer Incidence and Screening Neutropenia and Cancer Infections

Publication details

Journal / source
JNCI Journal of the National Cancer Institute
Publisher
Oxford University Press (OUP)
Volume
118
Issue
7
Pages
1278–1289
Publication date
28 February 2026
Language
EN